Bio-Techne names Steve Crouse president of Diagnostics and Spatial Biology segment
Bio-Techne said Dr. Matt McManus is transitioning from his role as president of the Diagnostics and Spatial Biology segment, and Steve Crouse, currently senior vice president of the Analytical Solutions Division, will take over that role effective March 1, 2026. The filing also discloses Crouse's employment terms, including a $505,000 base salary and a 75% target cash bonus, and that the board terminated McManus's employment without cause on February 9, 2026. The change is a leadership transition at a segment level and does not include any reported financial results.
Key points
- Steve Crouse appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
- Crouse's employment agreement, dated February 10, 2026, sets a $505,000 annual base salary and a target annual cash bonus of 75% of base salary
- Crouse's one-time equity awards include $85,000 at target in performance-based RSUs, plus stock options and time-vested RSUs with grant date values of approximately $42,500 each
- Dr. Matt McManus's employment was terminated without cause by board approval on February 9, 2026; he is eligible for severance and will remain to support the transition
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.